TGFB1 and diabetic kidney disease: This was shown in a clinical trial evaluating the efficacy of a neutralizing TGFβ1 antibody in patients with DKD, in which dosing that limited adverse effects was ineffective in slowing DKD (Voelker et al., 2017).